Literature DB >> 1325275

Immunohistochemical study of the human 17 beta-hydroxysteroid dehydrogenase and steroid receptors in endometrial adenocarcinoma.

O Mäentausta1, K Boman, V Isomaa, U Stendahl, T Bäckström, R Vihko.   

Abstract

17 beta-Hydroxysteroid dehydrogenase (17HSD) and estrogen (ER) and progestin (PR) receptors were analyzed immunohistochemically in tissue specimens of 66 patients with endometrial adenocarcinoma. Plasma steroid concentrations were correlated to immunohistochemical data. 17HSD was detected in 48% of the specimens and was stained in the cytoplasm of epithelial cells. The tissues were characterized by a heterogeneous staining pattern for 17HSD. In some patients, intensively stained epithelial cell clusters were seen, indicating that local factors were responsible for the expression of the protein. Poorly differentiated adenocarcinoma specimens tended to have no 17HSD more frequently than did well or moderately differentiated tissues. ER and PR were detectable in 24% and 28% of patients, respectively, and were localized in the nuclei of epithelial and stromal cells. There was a significant correlation between 17HSD and PR staining and an inverse correlation between plasma progesterone concentrations and 17HSD staining. This is contrary to the data obtained with normal endometrium. The main reason for this inverse relation between endometrial 17HSD staining and plasma progesterone concentrations was that, in some postmenopausal patients with low plasma progesterone concentrations, intense staining for 17HSD was detectable in the endometrial carcinoma specimens. This indicates a major difference in the regulation of 17HSD expression in endometrial adenocarcinomas, compared with normal tissues of premenopausal women.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325275     DOI: 10.1002/1097-0142(19920915)70:6<1551::aid-cncr2820700618>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

Review 1.  Regulation of 17β-hydroxysteroid dehydrogenases in cancer: regulating steroid receptor at pre-receptor stage.

Authors:  Mirja Rotinen; Joaquín Villar; Ignacio Encío
Journal:  J Physiol Biochem       Date:  2012-02-29       Impact factor: 4.158

2.  Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome.

Authors:  A M Gassel; J Backe; S Krebs; S Schön; H Caffier; H K Müller-Hermelink
Journal:  J Clin Pathol       Date:  1998-01       Impact factor: 3.411

3.  Novel hydroxysteroid (17beta) dehydrogenase 1 inhibitors reverse estrogen-induced endometrial hyperplasia in transgenic mice.

Authors:  Taija Saloniemi; Päivi Järvensivu; Pasi Koskimies; Heli Jokela; Tarja Lamminen; Sadaf Ghaem-Maghami; Roberto Dina; Pauliina Damdimopoulou; Sari Mäkelä; Antti Perheentupa; Harry Kujari; Jan Brosens; Matti Poutanen
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

4.  From Endocrinology to Intracrinology.

Authors:  Hironobu Sasano; Takashi Suzuki; Nobuhiro Harada
Journal:  Endocr Pathol       Date:  1998       Impact factor: 3.943

5.  Structure of the ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+.

Authors:  M W Sawicki; M Erman; T Puranen; P Vihko; D Ghosh
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-02       Impact factor: 11.205

6.  Expression, purification, and characterization of a human recombinant 17beta-hydroxysteroid dehydrogenase type 1 in Escherichia coli.

Authors:  Yi-Hsun Chang; Yuan-Liang Wang; Jain-Yu Lin; Lea-Yea Chuang; Chi-Ching Hwang
Journal:  Mol Biotechnol       Date:  2010-02       Impact factor: 2.695

7.  Oestrogen inactivation in the colon: analysis of the expression and regulation of 17beta-hydroxysteroid dehydrogenase isozymes in normal colon and colonic cancer.

Authors:  M A English; S V Hughes; K F Kane; M J Langman; P M Stewart; M Hewison
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.